Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Guidelines

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim

Clin Mol Hepatol. 2023;29(3):521-541. Published online July 1, 2023

Web of Science 9 Crossref 9

DOI: https://doi.org/10.3350/cmh.2023.0202

KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clin Mol Hepatol. 2023;29(3):542-592. Published online May 3, 2023

Web of Science 3 Crossref 5

DOI: https://doi.org/10.3350/cmh.2023.0087

Reviews

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

Web of Science 11 Crossref 10

DOI: https://doi.org/10.3350/cmh.2022.0391

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

Web of Science 15 Crossref 21

DOI: https://doi.org/10.3350/cmh.2022.0342

Acute hepatitis C virus infection: clinical update and remaining challenges

Chen-Hua Liu, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):623-642. Published online February 20, 2023

Web of Science 16 Crossref 17

DOI: https://doi.org/10.3350/cmh.2022.0349

A decade of liver organoids: Advances in disease modeling

Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan

Clin Mol Hepatol. 2023;29(3):643-669. Published online March 6, 2023

Web of Science 3 Crossref 3

DOI: https://doi.org/10.3350/cmh.2022.0428

Acute-on-chronic liver failure: Terminology, mechanisms and management

Vinay Kumar BR, Shiv Kumar Sarin

Clin Mol Hepatol. 2023;29(3):670-689. Published online March 20, 2023

Web of Science 15 Crossref 18

DOI: https://doi.org/10.3350/cmh.2022.0103

Editorial

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0173

Original Articles

Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis

Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2023;29(3):693-704. Published online March 9, 2023

Web of Science 8 Crossref 8

DOI: https://doi.org/10.3350/cmh.2022.0330

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Yu Jun Wong, Vy H. Nguyen, Hwai-I Yang, Jie Li, Michael Huan Le, Wan-Jung Wu, Nicole Xinrong Han, Khi Yung Fong, Elizebeth Chen, Connie Wong, Fajuan Rui, Xiaoming Xu, Qi Xue, Xin Yu Hu, Wei Qiang Leow, George Boon-Bee Goh, Ramsey Cheung, Grace Wong, Vincent Wai-Sun Wong, Ming-Whei Yu, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(3):705-720. Published online May 8, 2023

Web of Science 18 Crossref 23

DOI: https://doi.org/10.3350/cmh.2023.0004

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo

Clin Mol Hepatol. 2023;29(3):721-732. Published online March 22, 2023

Web of Science 204 Crossref 214

DOI: https://doi.org/10.3350/cmh.2023.0089

Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging

Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim

Clin Mol Hepatol. 2023;29(3):733-746. Published online May 8, 2023

Web of Science 9 Crossref 8

DOI: https://doi.org/10.3350/cmh.2023.0034

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

Web of Science 1 Crossref 2

DOI: https://doi.org/10.3350/cmh.2023.0121

Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis

Moon Haeng Hur, Yuri Cho, Do Young Kim, Jae Seung Lee, Gyoung Min Kim, Hyo-Cheol Kim, Dong Hyun Sinn, Dongho Hyun, Han Ah Lee, Yeon Seok Seo, In Joon Lee, Joong-Won Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(3):763-778. Published online May 30, 2023

Web of Science 3 Crossref 5

DOI: https://doi.org/10.3350/cmh.2023.0076

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study

Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim

Clin Mol Hepatol. 2023;29(3):779-793. Published online May 15, 2023

Web of Science 3 Crossref 4

DOI: https://doi.org/10.3350/cmh.2023.0110

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(3):794-809. Published online May 17, 2023

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0057

Letters to the Editor

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han

Clin Mol Hepatol. 2023;29(3):810-811. Published online May 8, 2023

Web of Science 1

DOI: https://doi.org/10.3350/cmh.2023.0129

Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Halil Haldun Emiroglu

Clin Mol Hepatol. 2023;29(3):812-812. Published online May 8, 2023

DOI: https://doi.org/10.3350/cmh.2023.0132

Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Hassam Ali

Clin Mol Hepatol. 2023;29(3):813-814. Published online May 19, 2023

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0120

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Amnuay Kleebayoon, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(3):815-816. Published online May 24, 2023

Web of Science 2 Crossref 1

DOI: https://doi.org/10.3350/cmh.2023.0170

Correspondences

Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(3):817-819. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0155

Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(3):820-820. Published online May 19, 2023

DOI: https://doi.org/10.3350/cmh.2023.0135

Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):821-822. Published online May 31, 2023

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2023.0183

Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):823-824. Published online May 31, 2023

Web of Science 1 Crossref 2

DOI: https://doi.org/10.3350/cmh.2023.0182

Snapshot

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0185

Erratums

Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(3):828-829. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054e
Corrects: Clin Mol Hepatol 2023;29(2):367

Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(3):830-830. Published online April 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345e
Corrects: Clin Mol Hepatol 2023;29(2):496

Viewed By 4992	MAFLD: How is it different from NAFLD?
Viewed By 4841	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4772	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4490	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4441	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 214	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 117	MAFLD: How is it different from NAFLD?
Cited By 95	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues